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Abstract
Aims: Vascular invasion by tumor cells is known to be important for cancer progression. By microarray and qPCR analyses,
we earlier identified an 18-gene signature associated with vascular involvement in endometrial cancer. Here, we explored
the significance of this vascular invasion signature in multiple series of breast cancer patients.
Methods and Results: The study includes 11 open access gene expression data sets which collectively provide information
on 2423 breast cancer patients. The 18-gene signature showed consistent associations with aggressive features of breast
cancer, like high tumor grade, hormone receptor negativity, HER2 positivity, a basal-like phenotype, reduced patient
survival, and response to neoadjuvant chemotherapy. Also, the vascular invasion signature was associated with several
other gene expression profiles related to vascular biology and tumor progression, including the Oncotype DX breast cancer
recurrence signature.
Conclusions: The 18-gene vascular invasion signature showed strong and consistent associations with aggressive features
of breast cancer and reduced survival.
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Introduction
Vascular invasion, i.e. tumor cells entering the vascular system,
is considered to be an early step in the metastatic process and
important for the progress of malignant tumors. When examined
on tissue sections as a morphologic marker, the presence of
vascular invasion is a strong prognostic factor in breast cancer and
other tumor types [1–4]. Recently, we presented a gene expression
signature related to vascular invasion in endometrial cancer, being
associated with aggressive tumor features and reduced survival [5].
This signature was generated from 57 primary endometrial
tumors, and the gene expression pattern was investigated by
microarray and qPCR, and subsequently related to the presence of
vascular invasion on tissue sections. Finally, 18 significantly and
differentially expressed genes were found between tumors with and
without such vascular involvement. Here, we explored whether
this 18-gene vascular invasion signature was associated with high-
grade features and poor survival in breast cancer, and we
examined a broad panel of publicly available data sets, collectively
representing a total of 2423 patients. The signature genes were
investigated in these external data sets and related to clinical data
and follow-up information. Briefly, the vascular invasion signature
was associated with markers of aggressive breast cancers and
reduced survival, and the vascular invasion score was also
associated with other published gene signatures related to vascular
involvement and tumor progression.
Materials and Methods
Vascular invasion signature
Generation of the 18-gene vascular invasion gene expression
signature was originally identified in a prospectively collected
patient series of 57 endometrial carcinomas by microarray and
qPCR analysis [5]. The vascular invasion signature consists of 7
up-regulated and 11 down-regulated genes (Table 1). The
vascular invasion signature was based on supervised analyses of
gene expression differences related to lymphatic and blood vessel
involvement (assessed on HE-sections) [5], and the signature
showed significant association with patient survival and aggressive
clinico-pathologic features, as well as with vascular and matrix
biology.
Gene expression data sets
Publicly available data sets with clinical information on breast
cancer patients were found and downloaded from the Gene
Expression Omnibus (GEO) website (www.ncbi.nlm.nih.gov/geo).
Overall, 11 breast cancer data sets with clinical information were
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e98787
identified and studied, including a total of 2423 patients. Gene
expression data from the following cohorts were analyzed:
GSE1456. A population based breast cancer series from 159
tumors with clinical information on histologic tumor grade,
molecular tumor subclasses (as described by Sørlie et al. [6]),
recurrence free survival, and breast cancer specific deaths [7].
GSE20271. Gene expression data on 178 breast cancer
patients, clinical stage I–III, from 6 different international sites
with data on histologic grade, estrogen receptor (ER), progester-
one receptor (PR) and human epidermal growth factor receptor 2
(HER2) status [8].
GSE20194. 230 stage I–III breast cancers from fine-needle
aspiration specimens before any therapy, with data on histologic
grade, ER, PR, and HER2-status [9].
GSE5460. 129 primary, untreated breast cancers, balanced for
nodal status, with information on tumor type and tumor size,
histologic grade, lymphatic vascular invasion (LVI), ER-status,
HER2-status, and lymph node status [10].
Table 1. The vascular invasion signature consists of 7 up-regulated and 11 down-regulated genes [5].
Gene symbol Gene name
Up-regulated genes
MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase)
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6
FPR2 Formyl peptide receptor 2
IL8 Interleukin 8
ANGPTL4 Angiopoietin-like 4
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
COL8A1 Collagen, type VIII, alpha 1
Down-regulated genes
OGN Osteoglycin
ATCAY Ataxia, cerebellar, Cayman type
MAMDC2 MAM domain containing 2
COL4A6 Collagen, type IV, alpha 6
C1orf114 Chromosome 1 open reading frame 114
KLHL13 Kelch-like 13 (Drosophila)
OSR2 Odd-skipped related 2 (Drosophila)
ALDH1A2 Aldehyde dehydrogenase 1 family, member A2
SEMA5A Sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain,
(semaphorin) 5A
FGFR2 Fibroblast growth factor receptor 2
ITIH5 Inter-alpha (globulin) inhibitor H5
doi:10.1371/journal.pone.0098787.t001
Table 2. Associations between histologic grade and the 18-gene vascular invasion signature score (mean signature score is given).
Grade
1 2 3 p-value1 Correlation6
GSE25066 (N = 508) 22.04 21.31 1.09 ,0.001 0.27
GSE22358 (N = 154) 21.55 20.82 2.27 0.001 0.31
GSE266392 (N = 226) 21.81 21.11 1.06 0.001 0.25
GSE14563 (N = 159) 21.23 21.03 1.32 ,0.001 0.25
GSE202714 (N = 178) 22.09 20.69 0.24 0.006 0.24
GSE 201944 (N = 230) 22.70 21.21 1.24 ,0.001 0.33
GSE54605 (N = 129) 22.57 20.86 1.39 0.001 0.25
1Kruskal-Wallis test, significance level 0.05,
2Histologic grade,
3Elston & Ellis tumor grade,
4Modified Black’s nuclear grade,
5Modified Bloom–Richardson grade,
6Spearman’s rho.
doi:10.1371/journal.pone.0098787.t002
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GSE7849. 78 tumors from women with early stage breast
cancer with information on histological type, nuclear grade, LVI,
ER-status, PR-status, lymph node status, and recurrence free
survival [11].
GSE20685. 327 primary breast cancers with data on molecular
subtypes, recurrence free survival and overall survival. The
molecular subtypes were classified in I-VI, where subtypes I and
II correspond to the basal-like and HER2 subtypes, subtype III
represents a mixture of HER2 and Luminal B, subtype IV is
similar to Luminal B, and subtype V and VI correspond to
Luminal A tumors [12].
GSE26639. 226 primary breast carcinomas in stage II–III, with
data on histologic grade, ER-status, PR-status, and HER2-status
[13].
GSE25066. 508 HER2-negative breast cancers with data on
tumor subclasses, ER-status, PR-status, and distant relapse free
survival [14].
GSE22358. 154 stage II–III breast cancers with data on
histologic grade, molecular subtype, ER-status, PR-status, HER2-
status, p53 status and response to treatment [15].
GSE17705. 298 ER-positive breast cancers treated with
tamoxifen for 5 years with data for distant relapse free survival
[16].
GSE12093. 136 ER-positive breast cancer patients treated with
tamoxifen with data on disease free survival [17].
Gene expression signatures related to tumor progression
We used the following published gene expression signatures to
investigate a possible correlation with the 18-gene vascular
invasion score: The VEGF signature identifies a compact in vivo
hypoxia signature highly expressed in metastatic breast tumors.
This signature is associated with poor outcome in multiple tumor
types [18]. Wound response signature; cancer invasion and metastasis
have demonstrated similarities with the wound healing process. A
published wound response signature predicts increased risk of
metastasis and death in several cancers [19]. NF-kB-regulated genes
Figure 1. High Vascular Invasion Signature score is associated with Basal-like and HER2 molecular subtypes. High signature score is
associated with Basal-like and HER2 molecular subtypes among data sets GSE25066, GSE22358, GSE1456 and GSE20685. Correlations were assessed
by Kruskal-Wallis test. Mean expression signature scores indicated by circles, and the bars represent standard error 62.
doi:10.1371/journal.pone.0098787.g001
Gene Expression Profiles in Breast Cancer
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are involved in tumor progression like proliferation, invasiveness,
angiogenesis, lymphangiogenesis and inflammation. The NF-kB-
associated gene signature contains 60 genes and is known to be of
importance for tumor progression in inflammatory breast cancer
[20]. Hypoxia gene signature; tumor hypoxia is an important feature
of human cancer progression. This published hypoxia gene
signature has demonstrated prognostic importance in breast and
ovary cancers [21]. BMI-1 driven gene signature; BMI-1 participates
in determining the proliferative potential and is required for self-
renewal of different stem cells. The BMI-1 driven gene signature
shows prognostic impact in many cancers [22]. Tumor stem cells
and stemness features are important for tumor progression [23].
Oncotype DX Recurrence Score corresponds to the likelihood of breast
cancer recurrence. The signature includes 5 reference and 16
cancer related genes [24].
Gene expression signature scores
The genes from the vascular invasion signature and the other
signatures, used for correlation studies, were mapped to the breast
cancer microarray data sets. A few genes in some of the signatures
could not be mapped to some of the data sets. Signature gene
expression scores were generated according to the algorithms
applied in the papers publishing the specific signatures. For the
vascular invasion signature, the hypoxia signature and the BMI-1
driven signature, summarized expression values for the down-
regulated genes were subtracted from the sum of expression values
for the up-regulated genes. For the wound response signature, a
summary expression signature was generated for the activated
genes. For the VEGF signature and the NF-kB-regulated genes, a
mean expression value from the expression values for the genes in
the signature was calculated. For the Oncotype DX recurrence
score, the algorithm in the paper was used on the 16 cancer-
related genes.
Statistics
Statistical analyses were performed with the PASW statistical
software package version 17 (SPSS Inc., Chicago, IL). Correlations
between categorical and continuous variables were assessed by
non-parametric tests; Mann-Whitney (two categorical groups) or
Kruskal-Wallis (.2 categorical groups) with a significance level of
0.05. Spearman’s correlation (rho) was also calculated between
tumor grade and the vascular invasion score. Linear association
between two continuous variables was evaluated by linear
regression analysis and Spearman’s correlation. Univariate
survival analyses were performed using the Kaplan-Meier method
(log-rank significance test), and scores were dichotomized based on
the upper quartile. Signature scores, together with standard
clinico-pathological and molecular variables, were further ana-
lyzed by log-log plot to determine how these variables could be
incorporated in Cox’ proportional hazards regression model, and
tested by the backward stepwise likelihood ratio test.
Results
Correlations to histologic grade and lymphatic vascular
invasion
Seven of the data sets had information on histologic or nuclear
tumor grade [7–10,13–15], and all sets showed significant
correlations between high signature score and high tumor grade
(Table 2).
Two data sets had information on lymphatic vascular invasion
(LVI), but there was no significant direct correlation between LVI
and the 18-gene signature score (data not shown) [10,11]. As
indicated, the original vascular invasion signature was based on
vascular invasion as a combination of lymphatic and blood vessel
involvement assessed on HE-sections [5].
Increased vascular invasion score is associated with
hormone receptor negative tumors
Seven of the data sets had information on ER-status [8–11,13–
15], and six of the sets showed significant correlations between
high signature score and ER-negative tumors, five of them highly
significant (p,0.001). The seventh data set did not show a
significant correlation (Table 3). For PR-status, there was
information available in six of the data sets [8,9,11,13–15]. All
sets showed a significant association between high signature score
and PR-negative tumors (Table 3).
Five data sets contained information about HER2-status [8–
10,13,15]. Two of them showed a significant correlation between
high signature score and HER2-positive tumors, one data set had
a borderline significant association, and two data sets did not show
any significant association between the signature score and HER2-
status (Table 3).
Figure 2. High Vascular Invasion Signature score is associated
with reduced survival. High signature score is associated with
reduced survival in datasets GSE1456 and GSE20685. Univariate survival
analysis was performed by the Kaplan-Meier method (log-rank
significance test). For each category, the number of cases is given
followed by the number of breast cancer deaths.
doi:10.1371/journal.pone.0098787.g002
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Figure 3. High Vascular Invasion Signature score is associated with reduced recurrence free survival. High signature score is associated
with reduced recurrence free survival in data sets GSE1456, GSE2506 and GSE20685. In data set GSE7849, there is a trend between high signature
score and reduced recurrence free survival. Survival curves are estimated by the Kaplan-Meier method (log-rank significance test). For each category,
the number of cases is given followed by the number of breast cancer deaths.
doi:10.1371/journal.pone.0098787.g003
Table 5. Multivariate survival analysis (Cox’ proportional hazards regression model) of the vascular invasion signature score.
Data set Variables HR1 95% CI2 P-value3
Disease specific survival
GSE14564 Vascular invasion score 2.7 1.2–6.1 0.019
Tumor grade 1.9 1.0–3.9 0.068
Overall survival
GSE206855 Vascular invasion score 2.0 1.3–3.2 0.002
Recurrence free survival
GSE14564 Vascular invasion score 1.9 1.0–3.9 0.063
Tumor grade 1.8 1.1–3.1 0.032
GSE206855 Vascular invasion score 1.8 1.2–2.9 0.010
1Adjusted Hazard ratio,
295% confidence interval,
3Lratio test, Final model after inclusion of: 4Vascular invasion score, histologic grade and molecular subtype or 5Vascular invasion score and molecular subtype.
Data presented for disease specific survival, overall survival and recurrence free survival.
doi:10.1371/journal.pone.0098787.t005
Gene Expression Profiles in Breast Cancer
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Increased vascular invasion score is associated with
molecular subtypes of breast cancer
Three of the data sets had information on molecular subtypes of
breast cancer such as Luminal A, Luminal B, HER2, basal-like,
and Normal breast-like [7,14,15]. All data sets showed highly
significant correlations between the subtypes and the vascular
invasion signature score, p,0.001 (Table 4). The most aggressive
basal-like and HER2 subtypes showed the highest signature score
and Luminal A, Luminal B and normal breast-like the lowest. A
fourth data set had molecular subtypes classified from I–VI [12].
When compared with the Sørlie classification [6], the results are
similar to the three data sets mentioned above (Table 4 and
Figure 1).
Increased vascular invasion score is associated with
reduced overall and recurrence free survival
Data set GSE1456 had information on breast cancer specific
deaths and data set GSE20685 had information on overall survival
[7,12]. A high signature score was significantly associated with
reduced survival in both these data sets (Kaplan-Meier method,
log-rank test, p,0.001 and p= 0.002; Figure 2). Also, four data
sets had information on recurrence free survival [7,11,12,16]. A
high signature score was associated with reduced recurrence free
survival in three data sets, whereas the fourth data set showed a
trend between reduced recurrence free survival and high signature
score (p = 0.079) (Figure 3).
Two data sets included ER-positive patients treated with
tamoxifen [16,17]. None of these data sets showed a significant
association between high signature score and probability of
recurrence (data not shown). In data set GSE25066, among
patients with ER positive tumors, high vascular invasion score was
significantly associated with reduced recurrence free survival,
p = 0.03 (data not shown). In data set GSE7849, no such
association was found (data not shown).
By multivariate survival analysis, using data sets with patient
survival (GSE1456 and GSE20685) or recurrence-free survival
(GSE1456, GSE20685, GSE25066 and GSE7849), selected
standard clinico-pathologic and molecular variables were included
together with the vascular invasion signature score (Table 5).
Initially, the vascular invasion score, histologic grade and
molecular subtype were included for data set GSE1456, and
vascular invasion score and molecular subtype were included for
data set GSE20685. Final models showed high vascular invasion
signature score to be an independent prognostic marker for
decreased survival, with Hazard ratio (HR) of 2.7, p= 0.019, in
data set GSE1456. For data set GSE20685, high vascular invasion
score showed a HR of 2.0, p= 0.002, for reduced survival
(Table 5).
For recurrence free survival, data set GSE1456 showed a
borderline significance for the signature score, with HR of 1.9,
p = 0.063, and in data set GSE20685 vascular invasion signature
score is an independent prognostic marker for recurrence free
survival with HR=1.8, p = 0.01. For data sets GSE25066 and
GSE7849, the vascular invasion signature was not an independent
prognostic factor for recurrence-free survival (data not shown).
Since Oncotype DX recurrence score predicts the risk of recurrent
disease in breast cancer, this signature was included in multivariate
survival analysis in the two data sets where vascular invasion score
was a prognostic marker for recurrence free survival. The vascular
invasion score still remained an independent prognostic marker for
recurrence free survival in data set GSE1456, while in data set
GSE20685, Oncotype DX recurrence signature score was an
independent prognostic marker, HR=1.8, p = 0.001 (data not
shown).
Correlation to treatment response
GSE20194: In 230 patients with 6 months of preoperative
chemotherapy (paclitaxel, 5-fluorouracil, cyclophosphamide and
doxorubicin) followed by surgical tumor resection [9], a high
vascular invasion signature score showed strong correlation with
pathological complete response (pCR) (p,0.001; Table 6).
GSE22358. 154 women received either neoadjuvant chemo-
therapy alone or chemotherapy in combination with trastuzumab
[15]. Among patients receiving chemotherapy only, a high
signature score showed a significant association with treatment
response (p = 0.017). Patients receiving chemotherapy plus trastu-
zumab showed a borderline significant relation between near
complete or complete response and high signature score
(p = 0.089) (Table 6).
Table 6. Association between the 18-gene signature score and response to treatment (mean signature score is given).
Response
GSE22358 (N=154) Neoadjuvant chemotherapy Chemotherapy + trastuzumab
npCR1/pCR2 NR3/PR4 p-value5 npCR/pCR NR/PR p-value5
3.25 21.15 0.017 3.17 20.12 0.089
GSE20271 (N=178) FAC treated T/FAC treated
pCR RD6 p-value pCR RD p-value
0.10 0.21 NS 20.26 20.02 NS
GSE 20194 (N=230) Neoadjuvant chemotherapy
pCR RD p-value
2.18 20.55 ,0.001
1Near-complete pathologic response,
2Pathologic complete response,
3No response,
4Partial respons,
5Mann-Whitney U test,
6Residual disease.
doi:10.1371/journal.pone.0098787.t006
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GSE20271. 273 patients were randomly given either weekly
paclitaxel 612 followed by fluorouracil, doxorubicin, and cyclo-
phosphamide 6 4 (T/FAC), or alone FAC66 as neoadjuvant
chemotherapy [8]. Of the 273 patients, 178 patients remained for
final analysis. Response to the treatment options FAC or T/FAC-
treated patients showed no correlation to the 18-gene signature
(Table 6).
Figure 4. Correlation between the Vascular Invasion Signature and tumor progression signatures. Vascular Invasion Signature score
shows a correlation to the VEGF signature, wound response signature, NF-Kb related genes, hypoxia gene signature, BMI-1 signature and Oncotype
DX Recurrence Score in breast cancer data sets; (A) GSE1456 and (B) GSE20685. The Spearman rank correlation test was used for bivariate correlations.
doi:10.1371/journal.pone.0098787.g004
Gene Expression Profiles in Breast Cancer
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Increased vascular invasion score is associated with other
tumor progression signatures
Six gene signatures related to tumor progression were mapped
in the two breast cancer data sets with survival information for
cancer specific death and overall survival (GSE1456 and
GSE20685), and the correlations between the signature scores
were explored. In data set GSE1456 (Figure 4A), all signatures
were significantly correlated to the vascular invasion score, with Rs
from 0.29–0.54. In data set GSE20685 (Figure 4B), all signatures
except the hypoxia score show significant correlation to the
vascular invasion score, with Rs from 0.36–0.50.
Discussion
Vascular invasion is a key hallmark of aggressive malignant
tumors and is considered an early marker of metastatic spread
through the lymphatic or blood vascular networks. In a previous
study of endometrial cancer [5], an 18-gene expression signature
was established by supervised strategy based on a correlation with
microscopic findings of tumor cells entering vascular structures
within the tumors. By further characterization of this vascular
invasion signature, expression motifs of vascular and matrix
biology were found, and the signature was associated with reduced
patient survival.
Since the vascular invasion signature appeared to capture
important features of aggressive tumors related to tumor-
microenvironment interactions, we asked whether the signature
could be of value in tumor types separate from those originally
studied. Here, in a study including 11 publicly available data sets
of breast cancer and information on altogether 2423 patients, we
found that the 18-gene vascular invasion signature showed strong
associations with features of aggressive breast cancer such as high
tumor grade, hormone receptor negativity, HER2 positive tumors,
presence of a basal-like phenotype, reduced patient survival and
response to neoadjuvant chemotherapy. This association pattern
was found in most data sets studied.
However, the small data set GSE7849 did not show significant
correlations between the vascular invasion signature score and ER
status as well as recurrence free survival. This data set contains a
low number of patients with early stage breast cancer. Differences
in selection and patient characteristics, in addition to lack of
power, might in part explain these negative findings.
Further, a significant association between HER2 and the
vascular invasion score was only seen in two of five data sets,
whereas ER and PR were associated with the signature in almost
all cohorts. Interestingly, HER2 positive breast cancers appear to
represent the subgroup with highest frequency of vascular invasion
by tumor cells as determined on tissue sections [25]. This could in
part explain the lack of significant differences in some series.
We also investigated the vascular invasion signature in three
data sets with information on response to treatment. The results
were not entirely conclusive, although two of the data sets,
including patients treated by neoadjuvant chemotherapy, showed
high signature scores in correlation with response.
Our findings support that the 18-gene vascular invasion score
reflects tumor-vascular interactions and angiogenesis, by signifi-
cant associations with gene signatures for VEGF-expression, the
wound-response process, NF-kB and tumor hypoxia. In addition,
the association with a BMI-1 related signature might indicate a
relation with stem cell phenotypes.
The Oncotype DX recurrence score predicts response to
chemotherapy and risk of distant recurrence in women with node
negative or node positive, ER-positive breast cancer [24,26]. The
correlation between our vascular invasion signature score and the
Oncotype DX recurrence score further validates that our signature
identifies aggressive breast cancers. In multivariate survival
analysis, the Oncotype DX recurrence score was included when
examining the two data sets where the vascular invasion signature
score was an independent prognostic factor for recurrence free
survival. In one of these data sets, the vascular signature score
maintained an independent association with prognosis, while in
the other data set, Oncotype DX was the independent prognostic
factor. This might indicate that both signatures capture aggressive
tumor subgroups without being completely overlapping. Of note,
in this study we investigated Oncotype DX cancer related genes by
microarray based data, whereas the approved Oncotype DX test is
performed by RT-PCR, hence it is difficult to directly compare the
two signature scores.
In an independent experimental study of luminal-like and basal-
like breast cancer xenograft models, basal-like tumors consistently
showed significantly higher baseline scores of the 18-gene vascular
invasion signature, when compared with luminal-like tumors [27].
While no clear associations between the vascular invasion score
and treatment response were observed for the basal-like model,
significantly higher scores were observed for luminal-like tumors
treated with doxorubicin. Interestingly, this result suggests that
vascular invasion could be paradoxically increased or selected for
in the doxorubicin treated luminal-like tumors [27].
In conclusion, an 18-gene vascular invasion signature showed
strong and consistent associations with aggressive features of breast
cancer. Our results indicate that this vascular invasion score might
reflect important biological characteristics involved in aggressive
tumors, probably related to vascular and matrix biology. The
practical value of this biomarker, in breast cancer and other tumor
types, should be further studied.
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